NASDAQ:CFRX
Delisted
ContraFect Corporation Stock News
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
11:30am, Wednesday, 17'th Jun 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
11:30am, Monday, 15'th Jun 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
12:00am, Monday, 15'th Jun 2020
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery...
Hedge Funds Never Been Less Bullish On ContraFect Corp (CFRX)
05:46pm, Wednesday, 10'th Jun 2020
In this article you are going to find out whether hedge funds think ContraFect Corp (NASDAQ:CFRX) is a good investment right now. We like to check what the smart money thinks first before doing extens
CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…
10:43am, Friday, 29'th May 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Four Abstracts Published in 30th ECCMID Abstract Book On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
11:30am, Tuesday, 26'th May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
11:10am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
02:59am, Friday, 22'nd May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
08:09pm, Thursday, 21'st May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
11:30am, Friday, 15'th May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
11:30am, Monday, 11'th May 2020
YONKERS, N.Y., May 11, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
01:09pm, Saturday, 02'nd May 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference
10:30am, Wednesday, 29'th Apr 2020
OCALA, FL / ACCESSWIRE / April 29, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral dis
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
